Smallcapvoice.com, Inc.

Denis Corin, CEO of Q BioMed Inc. (OTCQB: QBIO), called in to SmallCapvoice.com to go over his company’s business model, the markets they serve, their products and formulations including QBM-001, in support of Q BioMed's Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children, and Metastron. Q BioMed Inc., 'Q', is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need. Please visit http://www.qbiomed.com and sign up to receive regular updates. Follow us on social media @QBioMed. This interview may include forward looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "